Neutral
●
GlobeNewsWire
●
vor 5 Monaten
BRUSSELS, Belgium and CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (Nasdaq: BIIB) today announced that The Lancet, a world-leading medical journal, has published the full results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational, novel Fc-free CD40L inhibitor, in patients living with moderate-...